T.S. Wiley on Bio-identical Hormone Replacement Therapy for Patients With Breast Cancer

T.S. Wiley
Published: Sunday, Sep 27, 2015



T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Due to treatments that frequently block the estrogen receptor, several patients with breast cancer experience a change in hormonal status and a significant decrease in quality of life. Wiley discusses a study that examined between 57 and 112 women with breast cancer receiving biomemetic bio-identical hormone replacement therapy.

Results showed that these patients experienced a higher quality of life, Wiley says, mentioning a patient with triple-negative breast cancer who has been on the therapy for 10 years.


T.S. Wiley, CEO, Wiley Protocol Systems, discusses a study that examined the efficacy of biomemetic bio-identical hormone replacement therapy for patients with metastatic breast cancer.

Due to treatments that frequently block the estrogen receptor, several patients with breast cancer experience a change in hormonal status and a significant decrease in quality of life. Wiley discusses a study that examined between 57 and 112 women with breast cancer receiving biomemetic bio-identical hormone replacement therapy.

Results showed that these patients experienced a higher quality of life, Wiley says, mentioning a patient with triple-negative breast cancer who has been on the therapy for 10 years.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x